Abstract:3668 Background: To determine the activity and side-effect of intraperitoneal chemohyperthermia (IPCH) with oxaliplatin (LOHP), comparing with biweekly oxaliplatin, fluorouracil (FU) and leucovorin (LV) chemotherapy, as the therapy for patients with colorectal peritoneal carcinomatosis. Methods: 60 patients with measurable colorectal peritoneal carcinomatosis,proved pathologically, were divided into A and B groups at random. Group A: Patients were treated by IPCH with oxaliplatin 85 mg/m2, soluted in 500ml 5% GS, at an i.p. temperature of 42–44 degrees. Whereupon local radiofrequency hyperthermic chemotherapy was applied for 1 hours. Group B: Patients were treated with intravenous oxaliplatin 85 mg/m2 in 2 hours. During the hour preceding IPCH, all of them received an intravenous administration of 5-fluorouracil and leucovorin. The treatments were repeated every 2 weeks. One cycle lasts 30 days. Results: In group A, 27 patients can be evaluated. 2 patients achieved complete response, and 14 patients achieved partial response, for a response rate of 59.3%(95% CI, 29% to 68%). Median time to progression was 9.2 months (95% CI, 7.1 to 10.8 months) with median survival time of 11.1 months (95% CI, 8.4 to 19.7 months). In group B, 28 patients can be evaluated. 1 patients achieved complete response, and 9 patients achieved partial response, for a response rate of 35.7%(95% CI, 19% to 56%). Median time to progression was 7.0 months(95% CI, 4.1 to 12.5 months) with median survival time of 9.7 months(95% CI, 6.5 to 18.2 months).The response rate of ascites treatment was 86.7% with significant differences between two groups (P<0.05). Major toxicities included cumulative neuropathy grade 2 (9.4%) and grade 3 (1.2%); requiring discontinuation of oxaliplatin), diarrhea grade 3 to 4 (15.3%) and grade 3 to 4 hematologic toxicity (2.4%). Abdominal discomfort was significant(85.9%,p<0.05). Conclusions: The regimen of intraperitoneal chemohyperthermia (IPCH) with oxaliplatin (LOHP) seems to have activity comparable to intravenous programs of LOHP, combined with 5-fluorouracil and leucovorin. All side effects were tolerable. Prospective trials are warranted to determine the result. No significant financial relationships to disclose.

High-dose oxaliplatin induces severe hypersensitivity reactions and high recurrence rates during rechallenge in patients treated with hepatic arterial infusion chemotherapy

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions

Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study

Hypersensitivity Reactions to oxaliplatin: incidence and management

Oxaliplatin desensitization in patients with GI malignancies: Experience from a tertiary cancer center.

The incidence rate of allergic reactions induced by oxaliplatin is higher in patients with rectal cancer compared with colon cancer

Misdiagnosis of severe and atypical oxaliplatin‑related hypersensitivity reaction following chemotherapy combined with PD‑1 inhibitor: A case report and literature review

Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer

Hepatic Arterial Infusion of Chemotherapy As a Salvage Therapy for Patients with Advanced Hepatocellular Carcinoma

Hepatic Artery Infusion and Systemic XELOX Chemotherapy for Gastric and Colorectal Cancer with Liver Metastasis:Analysis of Curative Effect and Safety

Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports

Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan

A Pilot Study of Hepatic Arterial Infusion of Chemotherapy for Patients with Advanced Hepatocellular Carcinoma Who Have Failed Anti‐angiogenic Therapy

Intraperitoneal Chemohyperthermia (ipch) with Oxaliplatin for Patients with Colorectal Peritoneal Carcinomatosis.

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma

Hepatic arterial infusion chemotherapy with oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil in intermediate and advanced hepatocellular carcinoma: A retrospective study.

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer

Oxaliplatin-related Portal Hypertension Complicated with Esophageal Varices and Refractory Massive Ascites

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization